CSF3 and breast carcinoma: A prospective observational study investigated FN-related endpoints such as occurrence of neutropenic events, dose/delays issues, G-CSF protective effect and FN treatment burden in breast cancer and lymphoma patients in Europe (INC-EU study) [5].